JP6940406B2 - キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター - Google Patents

キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター Download PDF

Info

Publication number
JP6940406B2
JP6940406B2 JP2017524110A JP2017524110A JP6940406B2 JP 6940406 B2 JP6940406 B2 JP 6940406B2 JP 2017524110 A JP2017524110 A JP 2017524110A JP 2017524110 A JP2017524110 A JP 2017524110A JP 6940406 B2 JP6940406 B2 JP 6940406B2
Authority
JP
Japan
Prior art keywords
seq
vector
cells
car
hook
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017524110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528158A5 (enExample
JP2017528158A (ja
Inventor
アゴーゲ，ソフィー
ティバルディ，ロレンソ
エヴェン−デルモ，クレルヴィ
トルベツコイ，ドミトリー
ペレス，フランク
アミゴレーナ，セバスチャン
ボッシュ，セシル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Theravectys SA
Sorbonne Universite
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Theravectys SA
Sorbonne Universite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Curie, Theravectys SA, Sorbonne Universite filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2017528158A publication Critical patent/JP2017528158A/ja
Publication of JP2017528158A5 publication Critical patent/JP2017528158A5/ja
Priority to JP2020156063A priority Critical patent/JP7341110B2/ja
Application granted granted Critical
Publication of JP6940406B2 publication Critical patent/JP6940406B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017524110A 2014-07-25 2015-07-24 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター Expired - Fee Related JP6940406B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020156063A JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462028889P 2014-07-25 2014-07-25
US62/028,889 2014-07-25
US201562155811P 2015-05-01 2015-05-01
US62/155,811 2015-05-01
EP15306036 2015-06-29
EP15306036.3 2015-06-29
PCT/EP2015/067090 WO2016012623A1 (en) 2014-07-25 2015-07-24 Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156063A Division JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Publications (3)

Publication Number Publication Date
JP2017528158A JP2017528158A (ja) 2017-09-28
JP2017528158A5 JP2017528158A5 (enExample) 2018-08-30
JP6940406B2 true JP6940406B2 (ja) 2021-09-29

Family

ID=53514131

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017524110A Expired - Fee Related JP6940406B2 (ja) 2014-07-25 2015-07-24 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2020156063A Active JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2023078059A Withdrawn JP2023113656A (ja) 2014-07-25 2023-05-10 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020156063A Active JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2023078059A Withdrawn JP2023113656A (ja) 2014-07-25 2023-05-10 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Country Status (6)

Country Link
US (2) US10752668B2 (enExample)
EP (2) EP3172228B1 (enExample)
JP (3) JP6940406B2 (enExample)
CN (2) CN113846062B (enExample)
CA (1) CA2956385A1 (enExample)
WO (1) WO2016012623A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
KR20180108567A (ko) * 2015-10-22 2018-10-04 주노 테라퓨틱스 게엠베하 형질도입을 위한 방법, 키트, 제제 및 장치
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN108276493B (zh) 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
IL270142B2 (en) 2017-04-27 2025-05-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
IL270361B2 (en) 2017-05-01 2025-04-01 Univ Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
WO2019077164A1 (en) 2017-10-20 2019-04-25 Institut Curie CROCHET FUSION PROTEIN FOR REGULATING THE CELLULAR TRAFFIC OF A TARGET PROTEIN
US20200331975A1 (en) 2017-10-20 2020-10-22 Institut Curie Dap10/12 based cars adapted for rush
KR20200076732A (ko) 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
CA3088933A1 (en) 2018-01-17 2019-08-01 Aratinga Bio Tnp Polymer-encapsulated viral vectors for genetic therapy
EP3549597A1 (en) * 2018-04-06 2019-10-09 Heinrich-Heine-Universität Düsseldorf Synthetic signalling constructs and its use
AU2019253562B2 (en) * 2018-04-09 2025-11-27 The Trustees Of The University Of Pennsylvania Methods and compositions comprising a viral vector for expression of a transgene and an effector
BR112020020887A2 (pt) 2018-04-12 2021-04-06 Umoja Biopharma, Inc Vetores virais e linhagens celulares de empacotamento
WO2021009263A1 (en) 2019-07-16 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for cd38 and uses thereof
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
GB201914611D0 (en) * 2019-10-09 2019-11-20 Autolus Ltd Engineered immune cell
MX2022010936A (es) 2020-03-05 2022-11-16 Neotx Therapeutics Ltd ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas.
EP4208175A4 (en) * 2020-09-01 2025-05-07 The Trustees of The University of Pennsylvania IMPROVED GENERATION OF T-CELL TRANSDUCING LENTIVIRAL VECTORS USING A COCAL ENVELOPE
US20240084354A1 (en) 2020-11-13 2024-03-14 Honing Biosciences Means and methods for regulating intracellular trafficking of secretory or cell membrane-anchored proteins of interest
IT202100011576A1 (it) * 2021-05-06 2022-11-06 Univ Degli Studi Padova Nuova sequenza promotore per terapia genica
US20240415951A1 (en) 2021-11-15 2024-12-19 Theravectys Lentiviral vector for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
JP2025518033A (ja) * 2022-05-23 2025-06-12 ザ ジェネラル ホスピタル コーポレイション 免疫細胞クリスパースクリーニングのための方法及び組成物
AU2023316754A1 (en) 2022-07-27 2025-02-13 Institut Pasteur Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
US20250025158A1 (en) 2023-07-21 2025-01-23 Cilag Gmbh International Systems and subsystems for rolling a surgical instrument
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
WO2000020587A2 (en) * 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
EP1092779B1 (en) 1999-10-11 2009-11-25 Institut Pasteur Lentiviral vectors for the preparation of immunotherapeutical compositions
US6841359B2 (en) * 2000-10-31 2005-01-11 The General Hospital Corporation Streptavidin-binding peptides and uses thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005507236A (ja) * 2001-04-03 2005-03-17 キュラジェン コーポレイション 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
AU2002307625A1 (en) * 2002-03-08 2003-09-22 Cueros Industrializados Del Bajio Method of incorporating heat-stable particles into leather
US20050032173A1 (en) 2003-08-05 2005-02-10 Mauricio Rojas Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7265205B2 (en) * 2005-02-11 2007-09-04 Uti Limited Partnership Monomeric streptavidin muteins
ES2354954T3 (es) * 2006-03-22 2011-03-21 Viral Logic Systems Technology Corp. Métodos para identificar dianas polipeptídicas.
US7994317B2 (en) 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
EP2147683A1 (en) * 2008-07-25 2010-01-27 DKFZ Deutsches Krebsforschungszentrum Construct and method for the internalization of cargo molecules into a cell
EP2440667A1 (en) * 2009-06-11 2012-04-18 Institut Curie Methods and kits for regulating intracellular trafficking of a target protein
EP2651442B1 (en) * 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
US9409987B2 (en) * 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP2817330B1 (en) * 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
PL2884999T3 (pl) * 2012-08-20 2021-07-05 Fred Hutchinson Cancer Research Center Sposób i kompozycje do immunoterapii komórkowej
ES2824024T3 (es) * 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
HRP20201906T1 (hr) * 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
GB2557123B (en) * 2015-07-31 2021-11-03 Univ Minnesota Modified cells and methods of therapy

Also Published As

Publication number Publication date
JP2023113656A (ja) 2023-08-16
HK1248720A1 (zh) 2018-10-19
CN113846062B (zh) 2025-02-21
CN113846062A (zh) 2021-12-28
US20170166623A1 (en) 2017-06-15
EP3511413B1 (en) 2022-09-07
CA2956385A1 (en) 2016-01-28
WO2016012623A1 (en) 2016-01-28
JP2017528158A (ja) 2017-09-28
US20210009653A1 (en) 2021-01-14
EP3172228A1 (en) 2017-05-31
US10752668B2 (en) 2020-08-25
CN107531800B (zh) 2021-08-10
JP7341110B2 (ja) 2023-09-08
EP3172228B1 (en) 2019-02-27
CN107531800A (zh) 2018-01-02
EP3511413A1 (en) 2019-07-17
JP2021019590A (ja) 2021-02-18

Similar Documents

Publication Publication Date Title
JP7341110B2 (ja) キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
CN104379599B (zh) 能用于过继性细胞疗法的多肽
RU2708311C2 (ru) Химерные антигенные рецепторы с mnd-промотором
CN107074929B (zh) 嵌合自身抗体受体t细胞的组合物和方法
CN110526983B (zh) 改良型抗cd19 car-t细胞
KR20180021137A (ko) 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법
US20240101616A1 (en) Dap10/12 based cars adapted for rush
JP2023053328A (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
WO2017184553A1 (en) Cancer gene therapy targeting cd47
US20230174622A1 (en) Epidermal growth factor receptor
US12252517B2 (en) Hook fusion protein for regulating the cellular trafficking of a target protein
KR20210120019A (ko) 세포-특이적 전사 조절 서열 및 이의 용도
KR20250112252A (ko) 항-cd19 car-t 세포 치료법을 사용하는 루푸스 신염의 치료 방법
HK1248720B (zh) 用於嵌合抗原受体分子的调控表达的慢病毒载体
RU2774895C2 (ru) Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1, для лечения амилоидоза al
HK40063360A (en) Compositions and methods of chimeric autoantibody receptor t cells
Zhang Novel approaches to identify T cell-recognized tumor antigens and to redirect T cells for adoptive immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180713

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200519

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20200722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200722

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200917

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20201006

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201126

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210608

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210720

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210824

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210824

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210902

R150 Certificate of patent or registration of utility model

Ref document number: 6940406

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees